Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Riot Platforms Inc (RIOT) vs BIO-TECHNE Corp (TECH) Price & Performance

Riot Platforms IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Riot Platforms Inc vs BIO-TECHNE Corp — how do they compare? Riot Platforms Inc trades at $23.28 (market cap $8.12B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.

RIOTTECH
Market Cap
$8.12B$11.16B
Sector
TechnologyHealth
52-Week High
$28.67$72.12
52-Week Low
$11.03$43.31
Enterprise Value
$8.79B$11.24B
Dividend Yield
0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Riot Platforms Inc

RIOT trades at $19.90, up 8.98% in the past 24 hours, but faces a bearish technical signal despite strong analyst support. The company reported a significant net loss of $663.18 million in 2025 with negative profit margins, though revenue reached $647.44 million. Recent news highlights volatility and strategic partnerships in data center development.

Wall Street remains overwhelmingly bullish with 94% buy ratings and a $28.67 price target, but fundamental weaknesses and cash flow challenges present substantial risks. The stock's outlook depends on improving profitability and successful execution of its business expansion amid competitive pressures.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.

The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.

Returns comparison

Trailing returns across standard periods

About Riot Platforms Inc

Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.

Read more on RIOT

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH